Although these drugs are very effective, some people struggle to stick with the daily regimen. There are many reasons for ...

This is how a promising once-weekly HIV treatment could revolutionise medication adherence for patients, offering a simpler alternative to daily regimens.

A new, daily oral tablet that combines two current HIV treatment medications, bictegravir and lenacapavir (BIC/LEN), could effectively replace more complicated HIV treatment regimens used by people ...

Doctors Without Borders (MSF) has called for a drastic reduction in the price of a key medication used to prevent HIV ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment ...

HIV health providers have already absorbed some cuts and fear more. They worry that gains made toward eliminating the virus ...

With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead toward regulatory filings for the novel HIV regimen. In Gilead's ...

Monthly injections of antiviral drugs can keep HIV in check in people who struggle to stick to the standard treatment regimen of daily tablets 1. Therapies for HIV are safe and effective, but the ...

ViiV Healthcare received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, recommending marketing authorization for cabotegravir long-acting (LA) ...

JOHANNESBURG, SOUTH AFRICA – June 3, 2008 ““ Abbott today announced that the new tablet formulation of its protease inhibitor Aluvia(R) (lopinavir/ritonavir), for the treatment of HIV-1, is now ...

In closing out the TDF/TAF litigation chapter, Gilead is simultaneously moving to a new era of HIV treatment altogether with ...

The United Nations has set a goal for near universal HIV diagnosis and treatment for all by 2030. No country in Asia has hit ...